The HPV vaccine has reduced cervical cancer deaths to near-zero among young women in England who were vaccinated at age 12–13 [1].
This finding demonstrates the effectiveness of large-scale public health interventions in eliminating a specific cause of cancer death within a generation. By targeting children before exposure to the human papillomavirus, the program prevents the cellular changes that lead to malignancy.
The school-age vaccination programme in England began in 2008 [1]. Researchers tracked the impact of the vaccine on girls and young women, focusing on those who received the doses during the recommended window of 12–13 years [1].
According to the study, the initiative has saved approximately 200 lives in England [1]. The data indicates a dramatic shift in mortality rates for the youngest adult cohorts. Between 2020 and 2024, there were zero recorded cervical cancer deaths in women aged 20–24 [1].
Health experts said the widespread adoption of the vaccine cuts HPV infection. This reduction in viral prevalence prevents the development of cervical cancer and the associated deaths that previously affected this demographic [2].
The study covers deaths occurring up to 2024 [3]. The results highlight how the timing of the vaccine, administered well before the typical age of onset for cervical cancer, creates a significant protective barrier for women as they enter adulthood.
“The HPV vaccine has reduced cervical cancer deaths to near-zero among young women in England.”
The near-elimination of cervical cancer deaths in women aged 20–24 suggests that the HPV vaccine is achieving a level of preventative success rarely seen in oncology. If these trends hold, cervical cancer could become a negligible cause of death for future generations in England, potentially shifting the focus of public health resources toward screening the older, unvaccinated populations.
